Literature DB >> 24496301

Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

K Matsuda1, Y Nakazawa2, C Iwashita1, T Kurata2, K Hirabayashi2, S Saito2, M Tanaka2, K Yoshikawa2, R Yanagisawa2, K Sakashita2, S Sasaki3, T Honda1, K Koike2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24496301     DOI： 10.1038/leu.2014.58

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation.

Authors:  Kazuyuki Matsuda; Yozo Nakazawa; Kazuo Sakashita; Masaaki Shiohara; Kazuyoshi Yamauchi; Kenichi Koike
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

2.  SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.

Authors:  Norio Shiba; Kentaro Ohki; Myoung-Ja Park; Manabu Sotomatsu; Kazuko Kudo; Etsuro Ito; Masahiro Sako; Hirokazu Arakawa; Yasuhide Hayashi
Journal:  Br J Haematol       Date:  2013-10-14       Impact factor: 6.998

3.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Authors:  F Damm; R Itzykson; O Kosmider; N Droin; A Renneville; V Chesnais; V Gelsi-Boyer; S de Botton; N Vey; C Preudhomme; A Clavert; E Delabesse; S Park; D Birnbaum; M Fontenay; O A Bernard; E Solary
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

4.  SETBP1 mutation analysis in 944 patients with MDS and AML.

Authors:  F Thol; K J Suchanek; C Koenecke; M Stadler; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Kade; P Löffeld; S Banihosseini; G Bug; O Ottmann; W-K Hofmann; J Krauter; N Kröger; A Ganser; M Heuser
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

5.  Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.

Authors:  Hirotoshi Sakaguchi; Yusuke Okuno; Hideki Muramatsu; Kenichi Yoshida; Yuichi Shiraishi; Mariko Takahashi; Ayana Kon; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Hideki Makishima; Xinan Wang; Yinyan Xu; Sayoko Doisaki; Asahito Hama; Koji Nakanishi; Yoshiyuki Takahashi; Nao Yoshida; Jaroslaw P Maciejewski; Satoru Miyano; Seishi Ogawa; Seiji Kojima
Journal:  Nat Genet       Date:  2013-07-07       Impact factor: 38.330

6.  Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset.

Authors:  K Matsuda; S Matsuzaki; J Miki; E Hidaka; R Yanagisawa; Y Nakazawa; K Sakashita; T Kamijo; K Asami; K Sano; K Koike
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

7.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

Review 9.  Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.

Authors:  Kenichi Koike; Kazuyuki Matsuda
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

10.  The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

Authors:  Christian P Kratz; Charlotte M Niemeyer; Robert P Castleberry; Mualla Cetin; Eva Bergsträsser; Peter D Emanuel; Henrik Hasle; Gabriela Kardos; Cornelia Klein; Seiji Kojima; Jan Stary; Monika Trebo; Marco Zecca; Bruce D Gelb; Marco Tartaglia; Mignon L Loh
Journal:  Blood       Date:  2005-05-31       Impact factor: 22.113
View more
  3 in total

1.  Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.

Authors:  Christopher C Dvorak; Prakash Satwani; Elliot Stieglitz; Mitchell S Cairo; Ha Dang; Qinglin Pei; Yun Gao; Donna Wall; Tali Mazor; Adam B Olshen; Joel S Parker; Samir Kahwash; Betsy Hirsch; Susana Raimondi; Neil Patel; Micah Skeens; Todd Cooper; Parinda A Mehta; Stephan A Grupp; Mignon L Loh
Journal:  Pediatr Blood Cancer       Date:  2018-03-12       Impact factor: 3.167

2.  Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.

Authors:  Yozo Nakazawa; Kazuyuki Matsuda; Takashi Kurata; Akane Sueki; Miyuki Tanaka; Kazuo Sakashita; Chihaya Imai; Matthew H Wilson; Kenichi Koike
Journal:  J Hematol Oncol       Date:  2016-03-16       Impact factor: 17.388

3.  Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.

Authors:  Anna Hecht; Julia A Meyer; Astrid Behnert; Eric Wong; Farid Chehab; Adam Olshen; Aaron Hechmer; Catherine Aftandilian; Rukhmi Bhat; Sung Won Choi; Satheesh Chonat; Jason E Farrar; Mark Fluchel; Haydar Frangoul; Jennifer H Han; Edward A Kolb; Dennis J Kuo; Margaret L MacMillan; Luke Maese; Kelly W Maloney; Aru Narendran; Benjamin Oshrine; Kirk R Schultz; Maria L Sulis; David Van Mater; Sarah K Tasian; Wolf-Karsten Hofmann; Mignon L Loh; Elliot Stieglitz
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.